

INNOVATION Policy

« Together, we innovate for a better future »

Implemented April 2024 | Version 1.2

At ANS Biotech, we are committed to providing high-quality preclinical services in the field of pain. Our mission is to provide and develop innovative and effective pain models in close proximity to the clinical experience.

To achieve this mission, we have established a comprehensive policy that guides our work and ensures that we maintain the highest standards of quality, safety, and ethics.

Our policy is based on the following principles:

- 1. Collaboration:** We believe that collaboration is essential to achieving success in preclinical research. We work closely with our clients to understand their needs and goals, and we tailor our services to meet their specific requirements.
- 2. Innovation:** We are committed to staying at the forefront of new technologies and approaches in pain research. We invest in developing new technology to ensure that we can provide our clients with the most advanced and effective services.
- 3. Quality:** We are dedicated to maintaining the highest standards of quality in all aspects of our work. We follow rigorous quality control and quality assurance processes to ensure that the data we generate are accurate, reliable, and reproducible.
- 4. Safety:** We are committed to ensuring the safety and well-being of all animals used in our protocols. We adhere to strict ethical guidelines and regulations, and we use the most humane and appropriate methods available (3Rs).
- 5. Ethics:** We conduct our work with the highest level of integrity and ethical standards. We adhere to all applicable laws and regulations, and we maintain strict confidentiality and data protection policies.
- 6. Continuous improvement:** We believe that continuous improvement is essential to achieve excellence in preclinical research. We regularly review and update our policies and procedures to ensure that we are meeting the evolving needs of our clients and the scientific community.

Our policy is supported by a comprehensive quality management system that includes regular training, audits, and reviews. We are committed to maintaining open and transparent communication with our clients, and we welcome feedback and suggestions for improvement.

We are proud to be a trusted partner in preclinical pain research. We are dedicated to advancing the field of pain research through our collaborative and innovative approach.

Bernard van Iseghem
CEO
ANS Biotech S.A.